The high price of Gilead Sciences’ HIV drug Truvada has deterred many countries from providing the pill as a preventive treatment for people at high risk of contracting the AIDS-causing virus. By rolling out the preventive treatment as a clinical trial, the NHS can use the generic version of the drug without infringing patents.
from WSJ.com: US Business http://ift.tt/2vWw1Se
via IFTTT
No comments:
Post a Comment